HP Biotech made its debut at the 2025 Mevos Hangzhou International Medical Cosmetology Conference, reconstructing the aesthetic medicine industry chain ecosystem with synthetic biology technology.

2025-05-12

From May 9 to 11, 2025, the 20th Mevos International Medical Cosmetology Conference grandly opened at the Hangzhou International Expo Center. As a pioneer in the application of synthetic biology technology in China, Xi'an HP Biotech Group made a high-profile appearance with three core exhibition areas—the Class II & III Medical Device OEM/ODM Zone, the Yuexiyan and Yuesiting Brand Zone, and the Xinyasha Medical Device-Certified Repair Zone—comprehensively showcasing its innovative achievements in biotechnology and medical aesthetics, which has attracted extensive industry attention.

Innovation Drives Industry Transformation Sea Cucumber Peptide Technology Breaks Through Application Bottlenecks

As one of the first enterprises in China to use synthetic biology technology to prepare marine bio-collagen peptides, HP Biotech has successfully broken through the application bottlenecks of traditional marine bioactive ingredients with its independently developed HPStide® (sea cucumber peptide) technology. Its self-built small molecule peptide biosynthesis system enables precise control of raw material molecular weight (≥90% below 2000 Daltons). The technology has passed a full set of safety tests including acute eye irritation, repeated skin irritation, and skin allergy tests, ensuring the terminal products can be safely used on the skin. To date, the technology has been granted 4 invention patents. The group-led group standard *Quality Requirements for Sea Cucumber Peptide Raw Materials* has filled the domestic technological gap in the topical application of sea cucumbe

r peptides in skincare.

Diversified Layout Demonstrates Full Industry Chain Strength Three Booths Interpret Synergistic Value

In the core exhibition area of this conference, HP Biotech, relying on its synthetic biology full-industry-chain ecological platform, focused on showcasing its integrated solutions from raw material R&D to end products. In the OEM/ODM processing zone, HP Biotech systematically demonstrated its full-process service capabilities from raw material R&D to large-scale production. Through technical panels, physical samples, and case sharing, it highlighted core strengths such as customized formula design, regulatory compliance support, and production process optimization. Services cover multiple application scenarios including medical repair, anti-inflammatory and soothing, and women's intimate care. According to on-site feedback, the zone has attracted hundreds of medical aesthetic institutions and brand owners for negotiations, and multiple preliminary cooperation intentions have been reached.

In the brand exhibition area, HP Biotech leveraged technological empowerment to build a differentiated product matrix, demonstrating its diversified brand layout. Yuesiting, with the core philosophy of "Tang Dynasty-inspired Luxury Skin Beauty", integrates Tang aesthetics with the patented HPStide® (sea cucumber peptide) technology. It constructs a skin barrier repair system through the triple pathway of "hydration – repair – anti-wrinkle". Yuexiyan focuses on women's skincare and intimate care, adhering to the brand philosophy of "Caring for Women's Health – Medical Repair", providing consumers with medical skincare solutions for anti-inflammation, anti-aging, and anti-sensitivity. Xinyasha specializes in the medical aesthetics field, focusing on graded targeted repair. It has developed the ABC Ectodermal Repair Essence in accordance with Class II medical device standards, setting a new benchmark for "clinical-grade" repair after professional aesthetic procedures.

Technology-Driven Industrial Upgrading: The Medical Aesthetics Industry Enters an Era of Precision Cultivation

Data from this Mevos Conference shows that the growth of China's medical aesthetics market has shifted from high-speed expansion to a stage of high-quality development, with a significant increase in consumer demand for safety and efficacy traceability. HP Biotech's exhibition strategy precisely reflects this trend: its OEM/ODM business addresses the industry's challenges in implementing innovations, its consumer brands respond to the demand for precision skincare, and its medical brands fill the gap in standardized post-procedure repair. Through the cross-domain application of synthetic biology technology, HP Biotech has formed a full-chain layout covering "raw material R&D – medical devices – efficacy skincare". This model not only provides ordinary consumers with one-stop solutions ranging from basic repair to advanced anti-aging, but also offers a reference path for the industry's transformation and upgrading.

At the closing ceremony of the exhibition, a representative from HP Biotech's exhibition area stated: "HP Biotech will continue to increase R&D investment in recombinant biological materials such as recombinant sea cucumber peptide and recombinant sea cucumber collagen, as well as intelligent delivery technologies. We plan to launch several new medical device-certified products within 2025, and promote the standardized application of synthetic biology technology in the medical aesthetics field through industry-university-research-hospital collaboration mechanisms." As its brand philosophy puts it, "Leading bio-peptide technology for a more beautiful and healthier life", HP Biotech is taking technological innovation as its engine to write a new chapter in the high-quality development of China's medical aesthetics industry.